Novartis Financial Statements (NVS)
|
|
|
|
Report date
|
|
|
02.02.2022 |
01.02.2023 |
31.01.2024 |
31.01.2025 |
04.02.2026 |
|
28.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
43 974 |
43 461 |
46 660 |
51 722 |
54 811 |
|
56 053 |
|
Operating Income, bln rub |
|
|
10 056 |
7 946 |
9 769 |
14 544 |
17 074 |
|
17 121 |
|
EBITDA, bln rub |
? |
|
30 914 |
14 682 |
18 255 |
20 715 |
22 987 |
|
22 399 |
|
Net profit, bln rub |
? |
|
24 021 |
6 955 |
14 850 |
11 941 |
14 056 |
|
13 534 |
|
|
OCF, bln rub |
? |
|
15 071 |
14 236 |
14 458 |
17 619 |
19 242 |
|
19 165 |
|
CAPEX, bln rub |
? |
|
2 556 |
2 239 |
2 753 |
3 814 |
1 556 |
|
2 807 |
|
FCF, bln rub |
? |
|
12 515 |
11 997 |
11 705 |
13 805 |
17 686 |
|
16 358 |
|
Dividend payout, bln rub
|
|
|
7 368 |
7 506 |
7 255 |
7 624 |
7 858 |
|
8 722 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
30.7% |
107.9% |
48.9% |
63.8% |
55.9% |
|
64.4% |
|
|
OPEX, bln rub |
|
|
22 183 |
23 933 |
24 419 |
24 351 |
24 048 |
|
25 071 |
|
Cost of production, bln rub |
|
|
11 735 |
11 582 |
12 472 |
12 827 |
13 690 |
|
13 862 |
|
R&D, bln rub |
|
|
8 641 |
9 172 |
11 371 |
10 022 |
10 742 |
|
11 248 |
|
Interest expenses, bln rub |
|
|
905.0 |
834.6 |
876.1 |
1 036 |
1 187 |
|
1 222 |
|
|
Assets, bln rub |
|
|
131 795 |
117 453 |
99 945 |
102 246 |
115 569 |
|
118 532 |
|
Net Assets, bln rub |
? |
|
67 655 |
59 342 |
46 667 |
44 046 |
46 130 |
|
38 512 |
|
Debt, bln rub |
|
|
31 025 |
27 909 |
26 348 |
31 258 |
37 033 |
|
46 998 |
|
Cash, bln rub |
|
|
28 113 |
18 615 |
13 962 |
13 351 |
11 590 |
|
6 977 |
|
Net debt, bln rub |
|
|
2 912 |
9 294 |
12 386 |
17 907 |
25 443 |
|
40 021 |
|
|
Ordinary share price, rub |
|
|
82.8 |
|
|
97.3 |
137.9 |
|
152.0 |
|
Number of ordinary shares, mln |
|
|
2 243 |
2 181 |
2 077 |
2 018 |
1 939 |
|
1 909 |
|
|
Market cap, bln rub |
|
|
185 620 |
0 |
0 |
196 399 |
267 323 |
|
290 244 |
|
EV, bln rub |
? |
|
188 532 |
9 294 |
12 386 |
214 306 |
292 766 |
|
330 265 |
|
Book value, bln rub |
|
|
3 878 |
-1 603 |
-3 553 |
-7 625 |
-8 848 |
|
-28 516 |
|
|
EPS, rub |
? |
|
10.7 |
3.19 |
7.15 |
5.92 |
7.25 |
|
7.09 |
|
FCF/share, rub |
|
|
5.58 |
5.50 |
5.64 |
6.84 |
9.12 |
|
8.57 |
|
BV/share, rub |
|
|
1.73 |
-0.73 |
-1.71 |
-3.78 |
-4.56 |
|
-14.9 |
|
|
EBITDA margin, % |
? |
|
70.3% |
33.8% |
39.1% |
40.1% |
41.9% |
|
40.0% |
|
Net margin, % |
? |
|
54.6% |
16.0% |
31.8% |
23.1% |
25.6% |
|
24.1% |
|
FCF yield, % |
? |
|
6.74% |
|
|
7.03% |
6.62% |
|
5.64% |
|
ROE, % |
? |
|
35.5% |
11.7% |
31.8% |
27.1% |
30.5% |
|
35.1% |
|
ROA, % |
? |
|
18.2% |
5.92% |
14.9% |
11.7% |
12.2% |
|
11.4% |
|
|
P/E |
? |
|
7.73 |
0.00 |
0.00 |
16.4 |
19.0 |
|
21.4 |
|
P/FCF |
|
|
14.8 |
0.00 |
0.00 |
14.2 |
15.1 |
|
17.7 |
|
P/S |
? |
|
4.22 |
0.00 |
0.00 |
3.80 |
4.88 |
|
5.18 |
|
P/BV |
? |
|
47.9 |
0.00 |
0.00 |
-25.8 |
-30.2 |
|
-10.2 |
|
EV/EBITDA |
? |
|
6.10 |
0.63 |
0.68 |
10.3 |
12.7 |
|
14.7 |
|
Debt/EBITDA |
|
|
0.09 |
0.63 |
0.68 |
0.86 |
1.11 |
|
1.79 |
|
|
R&D/CAPEX, % |
|
|
338.1% |
409.6% |
413.0% |
262.8% |
690.4% |
|
400.7% |
|
|
CAPEX/Revenue, % |
|
|
5.81% |
5.15% |
5.90% |
7.37% |
2.84% |
|
5.01% |
|
| Novartis shareholders |
